The TIDE score is a tool developed for estimating the efficacy of tumor immune checkpoint therapies and is calculated on the basis of the presence of CAFs, MDSCs, and TAM M2 immune cells and the levels of CD8, IFNG, dysfunction and other indicators. This evidence concerns the gene IFNG and neoplasm.